Cargando…
Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide
Recently, the research community has become increasingly concerned with the receptor αvβ5, a member of the well-known integrin family. Different ongoing studies have evidenced that αvβ5 integrin regulates not only physiological processes but also a wide array of pathological events, suggesting the r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570809/ https://www.ncbi.nlm.nih.gov/pubmed/32961684 http://dx.doi.org/10.3390/molecules25184298 |
_version_ | 1783597032661843968 |
---|---|
author | Capasso, Domenica Del Gatto, Annarita Comegna, Daniela Russo, Luigi Fattorusso, Roberto Saviano, Michele Di Gaetano, Sonia Zaccaro, Laura |
author_facet | Capasso, Domenica Del Gatto, Annarita Comegna, Daniela Russo, Luigi Fattorusso, Roberto Saviano, Michele Di Gaetano, Sonia Zaccaro, Laura |
author_sort | Capasso, Domenica |
collection | PubMed |
description | Recently, the research community has become increasingly concerned with the receptor αvβ5, a member of the well-known integrin family. Different ongoing studies have evidenced that αvβ5 integrin regulates not only physiological processes but also a wide array of pathological events, suggesting the receptor as a valuable biomarker to specifically target for therapeutic/diagnostic purposes. Remarkably, in some tumors the involvement of the receptor in cell proliferation, tumor dissemination and angiogenesis is well-documented. In this scenario, the availability of a selective αvβ5 antagonist without ‘off-target’ protein effects may improve survival rate in patients with highly aggressive tumors, such as hepatocellular carcinoma. We recently reported a cyclic peptide, RGDechi15D, obtained by structure-activity studies. To our knowledge it represents the first peptide-based molecule reported in the literature able to specifically bind αvβ5 integrin and not cross react with αvβ3. Here we demonstrated the ability of the peptide to diminish both adhesion and invasion of HepG2 cells, an in vitro model system for hepatocellular carcinoma, to reduce the cell proliferation through an apoptotic process, and to interfere with the PI3K pathway. The peptide, also decreases the formation of new vessels in endothelial cells. Taken together these results indicate that the peptide can be considered a promising molecule with properties suited to be assessed in the future for its validation as a selective therapeutic/diagnostic weapon in hepatocarcinoma. |
format | Online Article Text |
id | pubmed-7570809 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75708092020-10-28 Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide Capasso, Domenica Del Gatto, Annarita Comegna, Daniela Russo, Luigi Fattorusso, Roberto Saviano, Michele Di Gaetano, Sonia Zaccaro, Laura Molecules Article Recently, the research community has become increasingly concerned with the receptor αvβ5, a member of the well-known integrin family. Different ongoing studies have evidenced that αvβ5 integrin regulates not only physiological processes but also a wide array of pathological events, suggesting the receptor as a valuable biomarker to specifically target for therapeutic/diagnostic purposes. Remarkably, in some tumors the involvement of the receptor in cell proliferation, tumor dissemination and angiogenesis is well-documented. In this scenario, the availability of a selective αvβ5 antagonist without ‘off-target’ protein effects may improve survival rate in patients with highly aggressive tumors, such as hepatocellular carcinoma. We recently reported a cyclic peptide, RGDechi15D, obtained by structure-activity studies. To our knowledge it represents the first peptide-based molecule reported in the literature able to specifically bind αvβ5 integrin and not cross react with αvβ3. Here we demonstrated the ability of the peptide to diminish both adhesion and invasion of HepG2 cells, an in vitro model system for hepatocellular carcinoma, to reduce the cell proliferation through an apoptotic process, and to interfere with the PI3K pathway. The peptide, also decreases the formation of new vessels in endothelial cells. Taken together these results indicate that the peptide can be considered a promising molecule with properties suited to be assessed in the future for its validation as a selective therapeutic/diagnostic weapon in hepatocarcinoma. MDPI 2020-09-19 /pmc/articles/PMC7570809/ /pubmed/32961684 http://dx.doi.org/10.3390/molecules25184298 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Capasso, Domenica Del Gatto, Annarita Comegna, Daniela Russo, Luigi Fattorusso, Roberto Saviano, Michele Di Gaetano, Sonia Zaccaro, Laura Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide |
title | Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide |
title_full | Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide |
title_fullStr | Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide |
title_full_unstemmed | Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide |
title_short | Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide |
title_sort | selective targeting of αvβ5 integrin in hepg2 cell line by rgdechi15d peptide |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570809/ https://www.ncbi.nlm.nih.gov/pubmed/32961684 http://dx.doi.org/10.3390/molecules25184298 |
work_keys_str_mv | AT capassodomenica selectivetargetingofavb5integrininhepg2celllinebyrgdechi15dpeptide AT delgattoannarita selectivetargetingofavb5integrininhepg2celllinebyrgdechi15dpeptide AT comegnadaniela selectivetargetingofavb5integrininhepg2celllinebyrgdechi15dpeptide AT russoluigi selectivetargetingofavb5integrininhepg2celllinebyrgdechi15dpeptide AT fattorussoroberto selectivetargetingofavb5integrininhepg2celllinebyrgdechi15dpeptide AT savianomichele selectivetargetingofavb5integrininhepg2celllinebyrgdechi15dpeptide AT digaetanosonia selectivetargetingofavb5integrininhepg2celllinebyrgdechi15dpeptide AT zaccarolaura selectivetargetingofavb5integrininhepg2celllinebyrgdechi15dpeptide |